Genomics Market Size, Share & Analysis Report, 2024-2033
The global genomics market size was estimated at USD 33.90 billion in 2023 and is projected to hit around USD 157.47 billion by 2033, growing at a CAGR of 16.6% during the forecast period from 2024 to 2033.
Key Takeaways:
Genomics Market Growth
The growth of genomics market is attributed to factors such as growing demand for gene therapy, personalized medicine, drug discovery, increasing cancer incidence, and a significant increase in demand for consumer genomics in recent years. Moreover, increasing number of joint ventures and partnerships amongst market players is also expected to have a positive impact on the genomics market growth. For instance, in June 2022, Illumina, Inc., and Allegheny Health Network signed a collaboration for effective evaluation of the impact of in-house Comprehensive Genomic Profiling (CGP) to leverage patient care.
The COVID-19 pandemic outbreak had posed challenges to applications of genomics technology in terms of research and therapeutics. Nevertheless, some niche applications were of great use to mankind during the pandemic situation to facilitate immediate attention for designing effective diagnostics, effective therapeutics and steps to curb the spread of COVID-19. For example, the viral genome mutational rate (~1-2 bases per month) was gauged for validity of PCR cycle was estimated to understand the efficacy of the re-purposed anti-viral treatments and thereby the vaccine development process was streamlined.
Many genomic surveillance programs were launched country wise to understand the dynamics of pandemic situation and to effective preventive measures. For instance, in December 2020, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) was launched by the joint efforts of Department of Biotechnology (DBT), Ministry of Health, and ICMR with an aim to screen the genomic variations in the SARS-CoV-2 by sequencing technologies. Furthermore, country specific companies are providing consumer genomics services which is also expected to fuel the market size in coming years. One such company being Mapmygenome which is one of the pioneers in India offers DTC genomics services.
The increasing prevalence of inherited cancers is expected create a high demand for cancer genomics. The substantial understanding of human genome have targeted focus on use of various gene therapies for treatment of cancers by modern gene editing techniques such as CRISPR-Cas gene technology. For instance, in September 2022, a group of researchers at the University of California introduced the applications of precision genome editing agents for management of inherited retinal diseases (IRDs).
The development of high-throughput sequencing technologies such as Next-Generation Sequencing (NGS) and microarrays has generated massive amounts of genomic data. However, the rapid accumulation of this data from DNA sequencing and Electronic Health Records (EHRs) poses significant challenges and opportunities for the extraction of biologically or clinically relevant information. Phenome-wide association study (PheWAS) & genome-wide association study (GWAS) are helping researchers to study correlations between genotype and phenotype.
The market players are extensively working towards collaborations, expansions, acquisitions and huge capital investments to advance in research to understand rare diseases and to aid drug discovery. For instance, PacBio declares a collaboration with the Genomics England society for the utility of PacBio’s technology to detect genetic variation in unexplained rare disorders. The study is intended to re-sequence a selection of samples collected during Genomics England’s 100,000 genomes project to discover potential operational and clinical benefits of long-read sequencing for the identification of mutations associated with rare diseases.
Genomics Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 39.53 Billion |
| Market Size by 2033 | USD 157.47 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 16.6% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Application, technology, deliverables, end-use, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Agilent Technologies; Bio-Rad Laboratories, Inc.; BGI Genomics; Color Genomics, Inc.; Danaher Corporation; Eppendorf AG; Eurofins Scientific; F. Hoffmann-La Roche Ltd.; GE Healthcare; Illumina Inc.; Myriad Genetics, Inc.; Oxford Nanopore Technologies; Pacific Biosciences of California, Inc.; QIAGEN N.V.; Quest Diagnostics Incorporated; Thermo Fisher Scientific, Inc.; 23andMe, Inc. |
Segments Insights:
Application Insights
The functional genomics segment dominated the overall market with the largest revenue share of 32.9% in 2023. The dominance of the segment can be attributed to research studies aiming to understand a particular phenotypical expression of a given disease condition. Many gene therapies for cancers are designed on the basis of functional genomic technology. For instance, in June 2020, researchers at European Molecular Biology Laboratory (EMBL) at Heidelberg increased the scalability and precision metrics of functional genomics CRISPR/Cas9 gene-based screens through targeted single-cell RNA sequencing. Single-cell RNA sequencing gives deep insights into levels of gene expression in individual cells and can capably analyze CRISPR/Cas9 functional genomics screens.
Pathway analysis segment is predicted to emerge as the most lucrative of all by 2033. Usage of pathway analysis in developing next-generation therapeutics has emerged one of the most growing applications. Pathway-based analysis has gained more attention after the emergence of clinical genomics and personalized therapies. This is mainly because genomics and personalized therapies aid in the in-depth analysis of the ability to navigate signaling pathways and disease networks.
Deliverables Insights
The product segment dominated the market in 2023. The products used in genomics are broadly segmented into two categories—instruments or systems that are required for the synthesis and sequencing of the nucleic acid sequences and consumables & reagents.
The increase in preference for personalized medicines and decline in costs of DNA sequencing owing to the launch of NGS technology resulted in the development of novel products or systems. The genomics market is gradually becoming more competitive with new product launches. For instance, in June 2022, PerkinElmer introduced an automated benchtop system for NGS, the research-use only BioQule NGS System to automate library preparation.
The service segment is expected to register a steady CAGR by 2033. The high cost of products, the demand for expertise required for genomics, and the focus on core operations by the end user are the major factors driving the services segment. NGS-based services held a major share in the genomics services segment due to the rapid adoption of Whole Genome Sequencing (WGS) and applications of sequence databases for disorder screening and prognosis. However, data processing and interpretation, rather than data production has become the need for current development and application.
End-user Insights
The pharmaceutical and biotechnology companies segment led the market in 2023. This is attributed to the increasing demand for use of genomics in drug discovery. Moreover, the market is driven by increasing adoption of spatial genomics & transcriptomics technologies. Numerous trials are underway for novel drug discovery using underlying knowledge from genomics. For instance, in June 2022, Illumina Inc., declares that it will present seven of their abstracts regarding the key oncology research at the American Society of Clinical Oncology (ASCO) 2022 in further to an event to discuss the transformational impact of comprehensive genomic profiling in precision medicine.
The hospital and clinic segment is estimated to grow at a substantial pace during the forecast period. Several hospitals and clinics are currently offering genomic sequencing services to patients and are using this technology in the daily practice of medicine. Stanford Medicine is one such facility that provides genomic sequencing services to patients with a rare or unidentified condition that is thought to be genetic. The first hospital system to offer the general public services for genetic sequencing, analysis, and interpretation is Partners HealthCare based in the U.S. It has enrolled over 200 patients and physicians in a study funded by NIH to study the integration of whole genome sequencing in clinical medicine.
Regional Insights
North America accounted for the largest market share of 42.69% in 2023. This is attributed to the support of research institutes and pharmaceutical giants. Genomics is now an integral part of any disease research and drug discovery due to the implications of genetic expression on human health. There are emerging advancements in the region for the utility of genomics with collaborative efforts. For instance, in January 2022, Illumina, Inc. collaborated with Nashville Biosciences, LLC, (part of Vanderbilt University Medical Center at Tennesee), for drug development by using genomics and to establish a preeminent clinico-genomic resource.
Asia Pacific is estimated to be the fastest-growing segment over the forecast period due to increased demand for genomics applications in diagnostics and the growing demand for novel therapeutic drugs to fight the increased incidence of diseases in the region. Several major human genome sequencing projects are being performed, one of the most recent projects is Genome Asia 100K. Under this project, 100,000 Asian genomes would be sequenced and analyzed, which can help accelerate population-specific medical advances and precision medicine. With this project, GA 100K was expected to identify new possible therapeutic drugs and understand the biology of diseases.
India Genomics Market
Indian market is anticipated to grow at significant growth rate over the forecast period. Over the past few decades, India has become a hub for pharmaceutical and biotechnology and has gained global attention due to the presence of skilled & knowledgeable manpower and low capital investments. Owing to the presence of rich resources and a large pool of existing R&D institutions in the country, India has become one of the key areas for setting up research laboratories & manufacturing units by multinational companies. Thus, rapidly growing pharmaceutical & biotechnology industries and frequent government initiatives to boost R&D activities in the country are expected to create lucrative opportunities in India genomics market.
Recent Development
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Genomics market.
By Application & Technology
By Technology
By Deliverables
By End-use
By Region
Chapter 1. Genomics Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Application & Technology
1.2.2. Deliverables
1.2.3. End use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Genomics Market: Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Genomics Market: Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Growing integration of genomics data into clinical workflows
3.3.1.1.1. More targeted and personalized healthcare
3.3.1.1.2. Growth of newborn genetic screening programs
3.3.1.1.3. Advancements in noninvasive cancer screening
3.3.1.1.4. Military genomics
3.3.1.2. Technological advances to facilitate genomic R&D
3.3.1.2.1. Emergence of advanced genome editing techniques
3.3.1.2.2. Integration of new data streams
3.3.1.2.3. RNA biology
3.3.1.2.4. Single-cell biology
3.3.1.3. Rising adoption of DIRECT-TO-CONSUMER genomics
3.3.1.4. Success of genetic tools in agrigenomics
3.3.1.5. Increasing participation of different companies
3.3.1.6. Increase in government role and funding in genomics
3.3.2. Market Restraint Analysis
3.3.2.1. Issues regarding intellectual property protection, data management, and public policies
3.3.2.2. Dearth of Public databases and personnel knowledge on machine learning algorithms
3.4. Industry Analysis Tools
3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.4.2. Porter's Five Forces Analysis
3.5. COVID-19 Impact Analysis
Chapter 4. Genomics Market: Application & Technology Business Analysis
4.1. Genomics Market: Application & Technology Market Share Analysis
4.2. Genomics Market Estimates & Forecast, By Application & Technology (USD Million)
4.3. Functional Genomics
4.3.1. Global Functional Genomics Market, 2020 - 2033
4.3.2. Transfection
4.3.2.1. Global Transfection Market, 2020 - 2033
4.3.3. Real-Time PCR
4.3.3.1. Global Real-Time PCR Market, 2020 - 2033
4.3.4. RNA Interference
4.3.4.1. Global RNA Interference Market, 2020 - 2033
4.3.5. Mutational Analysis
4.3.5.1. Global Mutational Analysis Market, 2020 - 2033
4.3.6. SNP Analysis
4.3.6.1. Global SNP Analysis Market, 2020 - 2033
4.3.7. Microarray Analysis
4.3.7.1. Global Microarray Analysis Market, 2020 - 2033
4.4. Epigenomics
4.4.1. Global Epigenomics Market, 2020 - 2033
4.4.2. Bisulfite Sequencing
4.4.2.1. Global Bisulfite Sequencing Market, 2020 - 2033
4.4.3. Chromatin Immunoprecipitation (ChIP & ChIP-Seq)
4.4.3.1. Global Chromatin Immunoprecipitation (ChIP & ChIP-Seq) Market, 2020 - 2033
4.4.4. Methylated DNA Immunoprecipitation (MeDIP)
4.4.4.1. Global Methylated DNA Immunoprecipitation (MeDIP) Market, 2020 - 2033
4.4.5. High-Resolution Melt (HRM)
4.4.5.1. Global High-Resolution Melt (HRM) Market, 2020 - 2033
4.4.6. Chromatin Accessibility Assays
4.4.6.1. Global Chromatin Accessibility Assays Market, 2020 - 2033
4.4.7. Microarray Analysis
4.4.7.1. Global Microarray Analysis Market, 2020 - 2033
4.5. Pathway Analysis
4.5.1. Global Pathway Analysis Market, 2020 - 2033
4.5.2. Bead-Based Analysis
4.5.2.1. Global Bead-Based Analysis Market, 2020 - 2033
4.5.3. Microarray Analysis
4.5.3.1. Global Microarray Analysis Market, 2020 - 2033
4.5.4. Real-time PCR
4.5.4.1. Global Real-time PCR Market, 2020 - 2033
4.5.5. Proteomics Tools (2-D PAGE; yeast 2-hybrid studies)
4.5.5.1. Global Proteomics Tools (2-D PAGE; yeast 2-hybrid studies) Market, 2020 - 2033
4.6. Biomarker Discovery
4.6.1. Global Biomarker Discovery Market, 2020 - 2033
4.6.2. Mass Spectrometry
4.6.2.1. Global Mass Spectrometry Market, 2020 - 2033
4.6.3. Real-time PCR
4.6.3.1. Global Real-time PCR Market, 2020 - 2033
4.6.4. Microarray Analysis
4.6.4.1. Global Microarray Analysis Market, 2020 - 2033
4.6.5. Statistical Analysis
4.6.5.1. Global Statistical Analysis Market, 2020 - 2033
4.6.6. Bioinformatics
4.6.6.1. Global Bioinformatics Market, 2020 - 2033
4.6.7. DNA Sequencing
4.6.7.1. Global DNA Sequencing Market, 2020 - 2033
4.7. Others
4.7.1. Global Others Market, 2020 - 2033
Chapter 5. Genomics Market: Deliverables Business Analysis
5.1. Genomics Market: Deliverables Market Share Analysis
5.2. Genomics Market Estimates & Forecast, By Deliverables (USD Million)
5.3. Products
5.3.1. Global Products Market, 2020 - 2033
5.3.2. Instruments/Systems/Software
5.3.2.1. Global Instruments/Systems/Software Market, 2020 - 2033
5.3.3. Consumables & Reagents
5.3.3.1. Global Consumables & Reagents Market, 2020 - 2033
5.4. Services
5.4.1. Global Services Market, 2020 - 2033
5.4.2. NGS-based Services
5.4.2.1. Global NGS-based Services Market, 2020 - 2033
5.4.3. Core Genomics Services
5.4.3.1. Global Core Genomics Services Market, 2020 - 2033
5.4.4. Biomarker Translation Services
5.4.4.1. Global Biomarker Translation Services Market, 2020 - 2033
5.4.5. Computational Services
5.4.5.1. Global Computational Services Market, 2020 - 2033
5.4.6. Others
5.4.6.1. Global Others Market, 2020 - 2033
Chapter 6. Genomics Market: End-use business Analysis
6.1. Genomics Market: End-use Market Share Analysis
6.2. Genomics Market Estimates & Forecast, By End-use (USD Million)
6.3. Clinical Research
6.3.1. Global Clinical Research Market, 2020 - 2033
6.4. Academic & Government Institutes
6.4.1. Global Academic & Government Institutes Market, 2020 - 2033
6.5. Hospitals & Clinics
6.5.1. Global Hospitals & Clinics Market, 2020 - 2033
6.6. Pharmaceutical & Biotechnology Companies
6.6.1. Global Pharmaceutical & Biotechnology Companies Market, 2020 - 2033
6.7. Others
6.7.1. Global Others Market, 2020 - 2033
Chapter 7. Genomics Market: Regional Business Analysis
7.1. Genomics Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. North America Genomics Market, 2020 - 2033
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. Genomics Market, 2020 - 2033
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Canada Genomics Market, 2020 - 2033
7.3. Europe
7.3.1. Europe Genomics Market, 2020 - 2033
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. UK Genomics Market, 2020 - 2033
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Germany Genomics Market, 2020 - 2033
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. France Genomics Market, 2020 - 2033
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Italy Genomics Market, 2020 - 2033
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Spain Genomics Market, 2020 - 2033
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Framework
7.3.7.4. Denmark Genomics Market, 2020 - 2033
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Framework
7.3.8.4. Sweden Genomics Market, 2020 - 2033
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Framework
7.3.9.4. Norway Genomics Market, 2020 - 2033
7.4. Asia Pacific
7.4.1. Asia Pacific Genomics Market, 2020 - 2033
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Japan Genomics Market, 2020 - 2033
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. China Genomics Market, 2020 - 2033
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. India Genomics Market, 2020 - 2033
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Australia Genomics Market, 2020 - 2033
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. Thailand Genomics Market, 2020 - 2033
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. South Korea Genomics Market, 2020 - 2033
7.5. Latin America
7.5.1. Latin America Genomics Market, 2020 - 2033
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil Genomics Market, 2020 - 2033
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Mexico Genomics Market, 2020 - 2033
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Argentina Genomics Market, 2020 - 2033
7.6. MEA
7.6.1. MEA Genomics Market, 2020 - 2033
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. South Africa Genomics Market, 2020 - 2033
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Saudi Arabia Genomics Market, 2020 - 2033
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. UAE Genomics Market, 2020 - 2033
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Kuwait Genomics Market, 2020 - 2033
Chapter 8. Competitive Landscape
8.1. Financial Performance
8.2. Participant Categorization
8.2.1. Market Leaders
8.2.1.1. Market share analysis, 2023
8.3. Participant’s Overview
8.3.1. Agilent Technologies
8.3.1.1. Overview
8.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.1.3. Technology Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Bio-Rad Laboratories, Inc
8.3.2.1. Overview
8.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.2.3. Technology Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. BGI Genomics
8.3.3.1. Overview
8.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.3.3. Technology Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Color Genomics, Inc
8.3.4.1. Overview
8.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.4.3. Technology Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Danaher Corporation
8.3.5.1. Overview
8.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.5.3. Technology Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Eppendorf AG
8.3.6.1. Overview
8.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.6.3. Technology Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. Eurofins Scientific
8.3.7.1. Overview
8.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.7.3. Technology Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. F. Hoffmann-La Roche Ltd.
8.3.8.1. Overview
8.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.8.3. Technology Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. GE Healthcare
8.3.9.1. Overview
8.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.9.3. Technology Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Illumina, Inc.
8.3.10.1. Overview
8.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.10.3. Technology Benchmarking
8.3.10.4. Strategic Initiatives
8.3.11. Myriad Genetics, Inc
8.3.11.1. Overview
8.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.11.3. Technology Benchmarking
8.3.11.4. Strategic Initiatives
8.3.12. Oxford Nanopore Technologies
8.3.12.1. Overview
8.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.12.3. Technology Benchmarking
8.3.12.4. Strategic Initiatives
8.3.13. Pacific Biosciences of California, Inc
8.3.13.1. Overview
8.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.13.3. Technology Benchmarking
8.3.13.4. Strategic Initiatives
8.3.14. QIAGEN N.V.
8.3.14.1. Overview
8.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.14.3. Technology Benchmarking
8.3.14.4. Strategic Initiatives
8.3.15. Quest Diagnostics Incorporated
8.3.15.1. Overview
8.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.15.3. Technology Benchmarking
8.3.15.4. Strategic Initiatives
8.3.16. Thermo Fisher Scientific, Inc
8.3.16.1. Overview
8.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.16.3. Technology Benchmarking
8.3.16.4. Strategic Initiatives
8.3.17. 23andMe, Inc
8.3.17.1. Overview
8.3.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.17.3. Technology Benchmarking
8.3.17.4. Strategic Initiatives
8.4. Strategy Mapping
8.4.1. Expansion
8.4.2. Acquisition
8.4.3. Collaborations
8.4.4. Product/service launch
8.4.5. Partnerships
8.4.6. Others
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers